治疗前乳腺MRI评估的腋窝淋巴结负荷与乳腺癌新辅助化疗后前哨淋巴结识别失败相关
该回顾性研究纳入2015年1月至2019年1月间新辅助化疗后行前哨淋巴结活检的276例乳腺癌患者,由两名放射科医生独立评估治疗前乳腺MRI上腋窝淋巴结特征。多因素分析显示,临床T分期较高(3或4期)、使用单示踪剂、可疑腋窝淋巴结数量较多(≥10枚)及存在结周浸润与SLN识别失败独立相关。
要点
- 治疗前MRI显示可疑腋窝淋巴结≥10枚或存在结周浸润,提示新辅助化疗后SLN识别失败风险高。
- 临床T分期为3或4期及使用单示踪剂亦与SLN识别失败独立相关。
关键影像表现/征象
- 两名放射科医生评估的治疗前MRI腋窝淋巴结特征包括数目、结周浸润、皮质厚度和最大径。
- 多因素分析显示,存在结周浸润与SLN识别失败相关(放射科医生1:OR=7.0,P=.002;放射科医生2:OR=7.5,P=.003)。
- 可疑腋窝淋巴结数量较多(≥10枚)与SLN识别失败相关(放射科医生1:OR=11.5,P=.002;放射科医生2:OR=8.3,P=.01)。
诊断标准与关键数值
- 临床T分期较高(3或4期)与SLN识别失败相关(放射科医生1:OR=5.2,P=.004;放射科医生2:OR=4.6,P=.01)。
- 使用单示踪剂与SLN识别失败相关(放射科医生1:OR=4.3,P=.04;放射科医生2:OR=3.9,P=.046)。
临床应用与阅片要点
- 阅片时注意计数可疑腋窝淋巴结数目,≥10枚者提示新辅助化疗后SLN识别失败风险高。
- 报告治疗前MRI时关注腋窝淋巴结结周浸润征象,存在结周浸润者SLN识别失败风险高。
- 结合临床T分期(3或4期)及示踪剂使用情况(单示踪剂)综合评估SLN识别失败风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background After publication of the findings of the American College of Surgeons Oncology Group Z1071 trial, sentinel lymph node biopsy (SLNB) has been increasingly performed in patients with breast cancer after neoadjuvant chemotherapy (NAC). Purpose To investigate the pretreatment breast MRI and clinical-pathologic characteristics associated with failed sentinel node identification after NAC in patients with breast cancer. Materials and Methods Patients who underwent SLNB after NAC between January 2015 and January 2019 were retrospectively identified. Two radiologists independently reviewed the characteristics of axillary nodes (number, perinodal infiltration, cortical thickness, and maximal diameter) at pretreatment breast MRI. The associations of the clinical-pathologic and imaging characteristics of the axillary nodes with sentinel node identification were assessed by using the χ2 test and/or the χ2 test for trend and multivariable logistic regression with odds ratio (OR) calculation. Results A total of 276 women (mean age ± standard deviation, 48 years ± 9; range, 27-68 years) were included. Sentinel nodes were identified in 252 of the 276 patients (91%). Multivariable analysis showed that higher (stage 3 or 4) clinical T stages (OR = 5.2, P = .004 for radiologist 1; OR = 4.6, P = .01 for radiologist 2), use of a single tracer (OR = 4.3, P = .04 for radiologist 1; OR = 3.9, P = .046 for radiologist 2), a greater number (10 or more) of suspicious axillary nodes (OR = 11.5, P = .002 for radiologist 1; OR = 8.3, P = .01 for radiologist 2), and the presence of perinodal infiltration (OR = 7.0, P = .002 for radiologist 1; OR = 7.5, P = .003 for radiologist 2) were associated with failed sentinel node identification. Conclusion A greater number of suspicious axillary nodes and the presence of perinodal infiltration at pretreatment MRI, higher clinical T stages, and use of a single tracer were independently associated with failed sentinel node identification after neoadjuvant chemotherapy in patients with breast cancer. © RSNA, 2020 See also the editorial by Imbriaco in this issue.
引用
- Kim WH, Kim HJ, Park CS, et al. Axillary Nodal Burden Assessed with Pretreatment Breast MRI Is Associated with Failed Sentinel Lymph Node Identification after Neoadjuvant Chemotherapy for Breast Cancer. Radiology. 2020. PMID: 32125253. doi:10.1148/radiol.2020191639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。